Study 4 of 7Retatrutide (LY3437943) literatureBMJ (Clinical research ed.)Top journal2026
Retatrutide fact check: Has a man died after taking the unapproved weight loss jab?
Not reported in abstract.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpus4
Preclinical · this one
0
Observational
0
Open-label
0
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.20). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
- Not reported in abstract.
Elsewhere in the Retatrutide (LY3437943) corpus
DRetatrutide: Obesity drug opens to "compassionate use" in US after speculation Trump took it.BMJ (Clinical research ed.) · 2026—CEffects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.Behavioural brain research · 2026 · Retatrutide-treated diabetic rats showed preserved overall Morris Water Maze performance relative to untreated diabetic rats.AnimalAComparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2026 · n=99791 · Emerging agents (ecnoglutide, mazdutide, retatrutide) may produce 13.1-14.6% weight loss; very low to low certainty.reviewDMedical Treatments for Obesity: What Does the Future Have in Store?The Journal of clinical endocrinology and metabolism · 2026 · Retatrutide produced weight reductions exceeding 25%.reviewDBeyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology · Not reported in abstract.reviewDBeyond weight loss: multisystem benefits of obesity medications.The lancet. Diabetes & endocrinology · 2026—